ESCMID eLibrary

Search results
Icon explanation








-
P2769
Selection of EUCAST disk potency for WCK 4282 (cefepime-tazobactam, FEP-TAZ) susceptibility testing against Enterobacterales and Pseudomonas aeruginosa
16 April 2019
Session: Disk diffusion sucseptibility testing
-
P2770
Selection of EUCAST disk potency for WCK 5222 (cefepime-zidebactam, FEP-ZID) susceptibility testing against Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii
16 April 2019
Session: Disk diffusion sucseptibility testing
-
O1063
WCK-771 (INN: levonadifloxacin): pharmacodynamic index (PDI) and PD target (PDT) determination studies involving methicillin /quinolone-resistant Staphylococcus aureus (MRSA/QRSA) employing neutropenic mouse lung infection model
16 April 2019
Session: Defining exposure, efficacy and safety of new antimicrobial agents
-
P1941
Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses to support WCK-771 (INN: levonadifloxacin) clinical dose selection
15 April 2019
Session: Recent research on the pharmacokinetics and safety of antibacterial agents
-
OS1017
WCK 4873 (Nafithromycin): PK/PD analysis for H. influenzae (HI) through murine lung infection model
25 April 2017
Session: PK/PD: what you need to learn for new and old-revived antibiotics
-
OS1016
WCK 4282 [high-dose Cefepime (FEP)-Tazobactam (TAZ)]: In-vivo PK/PD studies identifying TAZ threshold concentrations (CT) against AmpC P. aeruginosa (PA)
25 April 2017
Session: PK/PD: what you need to learn for new and old-revived antibiotics
-
P1350
WCK 4873 (Nafithromycin): Impact of hyper ermB induction in S. pneumoniae and S. aureus on the activity of ketolides
24 April 2017
Session: Various agents against Gram-positive bacteria
-
P1302
A novel beta-lactam enhancer Gram-negative antibiotic, zidebactam (ZID) - phenotypic and genotypic characteristics of ZID-selected mutants of Enterobacteriaceae - expressing Class C, KPC and NDM
24 April 2017
Session: Zidebactam and other new Gram-negative antibiotic potentiators
-
P1264
WCK 4282 (high-dose Cefepime-Tazobactam): Complimentary features drive efficacy against KPC-producing pathogens
11 April 2016
Session: Cefepime-tazobactam
-
P1302
Young doctors’ perspectives on antibiotic use and resistance in Europe in 2015 (YPAR): preliminary results
11 April 2016
Session: Education and competencies in antimicrobial stewardship
Search narrowed by
-
Topics
-
Type of material
-
Time period